Therapeutic transplantation using developing, human or porcine, renal or hepatic, grafts
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-035/54
A61K-035/407
A61K-035/12
C12N-005/073
출원번호
UP-0037025
(2005-01-19)
등록번호
US-7780993
(2010-09-13)
발명자
/ 주소
Reisner, Yair
Dekel, Benjamin
Eventov-Friedman, Smadar
Katchman, Helena
Shezen, Elias
Aronovich, Anna
Tchorsh, Dalit
출원인 / 주소
Yeda Research and Development Co. Ltd.
인용정보
피인용 횟수 :
4인용 특허 :
14
초록
A method of treating a renal, hepatic or enzyme-deficiency disorder in a subject in need thereof is disclosed. The method is effected by transplanting into the subject tissue derived from a human or porcine, kidney or liver, the kidney or liver being at a selected gestational stage.
대표청구항▼
What is claimed is: 1. A method of alleviating or stabilizing a hepatic, or hepatic enzyme-deficiency disorder in a subject in need thereof, the method comprising transplanting hepatic organ precursor/tissue into the subject, said hepatic organ precursor/tissue being derived from a porcine liver be
What is claimed is: 1. A method of alleviating or stabilizing a hepatic, or hepatic enzyme-deficiency disorder in a subject in need thereof, the method comprising transplanting hepatic organ precursor/tissue into the subject, said hepatic organ precursor/tissue being derived from a porcine liver being at a stage of development of 28 days of gestation. 2. The method of claim 1, further comprising treating the subject with an immunosuppressive regimen prior to, concomitantly with or following said transplanting said hepatic organ precursor/tissue into the subject, thereby promoting engraftment of said organ precursor/tissue in the subject. 3. The method of claim 2, wherein said treating the subject with an immunosuppressive regimen is effected by administering at least one immunosuppressant drug to the subject. 4. The method of claim 3, wherein said at least one immunosuppressant drug is capable of blocking binding of a lymphocyte coreceptor with a ligand of said lymphocyte coreceptor. 5. The method of claim 4, wherein said at least one immunosuppressant drug is capable of blocking binding of a lymphocyte coreceptor with a ligand of said lymphocyte coreceptor, and wherein said administering said at least one immunosuppressant drug to the subject is effected during a time period selected from a range of 1 to 60 days. 6. The method of claim 4, wherein said lymphocyte coreceptor is selected from the group consisting of CD28 and CD40. 7. The method of claim 4, wherein said ligand of said lymphocyte coreceptor is selected from the group consisting of B7-1 and CD40L. 8. The method of claim 3, wherein said at least one immunosuppressant drug comprises CTLA4-Ig. 9. The method of claim 3, wherein said at least one immunosuppressant drug comprises CTLA4-Ig and anti-CD40L antibody. 10. The method of claim 3, wherein said at least one immunosuppressant drug comprises CTLA4-Ig, anti-CD40L antibody and rapamycin. 11. The method of claim 1, wherein said transplanting said hepatic organ precursor/tissue into the subject is effected by transplanting said hepatic organ precursor/tissue into an anatomical location of the subject selected from the group consisting of the portal vein, the liver, the renal capsule, the sub-cutis, the omentum, the spleen, and the intra-abdominal space. 12. The method of claim 1, wherein the subject is a mammal. 13. The method of claim 1, wherein said porcine liver is non-syngeneic with the subject. 14. The method of claim 1, wherein said porcine liver is xenogeneic with the subject. 15. A method of alleviating or stabilizing a hepatic, or hepatic enzyme-deficiency disorder in a subject in need thereof, the method comprising transplanting non-cultured hepatic organ precursor/tissue into the subject, said non-cultured hepatic organ precursor/tissue being derived from a porcine liver being at a stage of development of 28 days of gestation. 16. The method of claim 15, further comprising treating the subject with an immunosuppressive regimen prior to, concomitantly with or following said transplanting said non-cultured hepatic organ precursor/tissue into the subject, thereby promoting engraftment of said organ precursor/tissue in the subject. 17. The method of claim 16, wherein said treating the subject with an immunosuppressive regimen is effected by administering at least one immunosuppressant drug to the subject. 18. The method of claim 17, wherein said at least one immunosuppressant drug is capable of blocking binding of a lymphocyte coreceptor with a ligand of said lymphocyte coreceptor. 19. The method of claim 18, wherein said at least one immunosuppressant drug is capable of blocking binding of a lymphocyte coreceptor with a ligand of said lymphocyte coreceptor, and wherein said administering said at least one immunosuppressant drug to the subject is effected during a time period selected from a range of 1 to 60 days. 20. The method of claim 18, wherein said lymphocyte coreceptor is selected from the group consisting of CD28 and CD40. 21. The method of claim 18, wherein said ligand of said lymphocyte coreceptor is selected from the group consisting of B7-1 and CD40L. 22. The method of claim 17, wherein said at least one immunosuppressant drug comprises CTLA4-Ig. 23. The method of claim 17, wherein said at least one immunosuppressant drug comprises CTLA4-Ig and anti-CD40L antibody. 24. The method of claim 17, wherein said at least one immunosuppressant drug comprises CTLA4-Ig, anti-CD40L antibody and rapamycin. 25. The method of claim 15, wherein said transplanting said non-cultured hepatic organ precursor/tissue into the subject is effected by transplanting said non-cultured hepatic organ precursor/tissue into an anatomical location of the subject selected from the group consisting of the portal vein, the liver, the renal capsule, the sub-cutis, the omentum, the spleen, and the intra-abdominal space. 26. The method of claim 15, wherein the subject is a mammal. 27. The method of claim 15, wherein said porcine liver is non-syngeneic with the subject. 28. The method of claim 15, wherein said porcine liver is xenogeneic with the subject. 29. The method of claim 1, wherein said subject is a human subject. 30. The method of claim 15, wherein said subject is a human subject.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (14)
Sachs David H., Allogeneic and xenogeneic transplantation.
Chen Lieping ; Hellstrom Ingegerd ; Hellstrom Karl Erik ; Ledbetter Jeffrey A. ; Linsley Peter S., Inhibition of tumor cell growth by administration of B7-transfected cells.
Smikodub Alexandr Ivanovich,UAX ; Markov Igor Semenovich,UAX ; Pilipchak Elena Makarovna,UAX, Pharmaceutical preparation based on fetal suspension and methods of treating acquired immune deficiency syndrome (HIV in.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.